Clinical and laboratory features of patients before and after TCZ
| M0 (previous treatment) | M6 | M12 | M0 (previous treatment) | M6 | M12 | |
|---|---|---|---|---|---|---|
| TCZ treatment | NSAID, steroids, methotrexate, hydroxychloroquine, etanercept, adalimumab | TCZ, steroids (low dose at 5 mg/day), hydroxycholoroquine | NSAID, steroids, methotrexate, hydroxychloroquine, mycophenolate mofetil, etanercept | TCZ, steroids (low dose at 5 mg/day), hydroxychloroquin, methotrexate | ||
| Age (years) | 15 | 16 | 17 | 15 | 15 | 16 |
| Joint manifestation (cJADAS)* | 20 | 0 | 0 | 14 | 1 | 0 |
| Raynaud's phenomenon | + | + | + | + | + | + |
| Haematology | ||||||
| Hb (g/L) | 129 | 115 | 119 | 125 | 116 | 135 |
| WCC (g/L) | 5.04 | 3.14 | 2.3 | 6.17 | 7.5 | 7.17 |
| Lymphocytes (g/L) | 2.36 | 1.35 | 1.15 | 1.79 | 2.3 | 1.51 |
| Platelet | 369 | 290 | 229 | 400 | 394 | 262 |
| Biochemistry | ||||||
| CRP (<5 mg/L) | 36.2 | <0.2 | <0.2 | 18.6 | <0.2 | <0.2 |
| ASAT (<40 U/L) | 31 | 24 | 28 | 101 | 145 | <40 |
| ALAT (<40 U/L) | 13 | 17 | 25 | 88 | 326 | <40 |
| CK (<200 U/L) | 1292 | 98 | 80 | |||
| Immunology | ||||||
| ANA | 1/1600 | 1/1280 | 1/1280 | 1/1600 | 1/1280 | 1/1280 |
| dsDNA Ab RIA (Farr assay >7 UI/mL) | 30 | 85 | >97 | 7.4 | 7.1 | 7 |
| Anti-SSA 60 kDa | − | − | − | >2 | >2 | 3.7 |
| Anti-U1RNP | >8 | 4 | >2 | >2 | >8 | |
| Cryoglobulinaemia | − | + (type III) | + (type III) | − | − | − |
*The clinical (3-variable) cJADAS: inactive disease <1, low disease activity <2.5, moderate disease activity 2.51–8.5, high disease activity >8.5.
Ab, antibody; ALAT, alanine aminotransferase; ANA, antinuclear antibody; ASAT, aspartate aminotransferase; cJADAS,clinical (3-variable) Juvenile Arthritis Disease Activity Score; CK, creatine kinase; CRP, C reactive protein, ds, double-stranded; Hb, haemoglobin; NSAID, non-steroidal anti-inflammatory drugs; RIA, radioimmunoassay; SSA, anti-Sjögren's-syndrome-related antigen A; TCZ, tocilizumab; Anti-U1 RNP, Anti-U1 small nuclear ribonucleoprotein; WCC, white cell count.